文献速递冠心病血脂与心血管预防

银屑病生物制剂治疗与冠状动脉炎症的关联:基于血管周围脂肪衰减指数的研究

Association of Biologic Therapy With Coronary Inflammation in Patients With Psoriasis as Assessed by Perivascular Fat Attenuation Index.
PubMed 文献 · JAMA Cardiol · 2019-01-01

这项前瞻性队列研究纳入134例中重度银屑病患者,82例接受生物制剂治疗1年,52例仅局部或光疗。采用冠状动脉CT血管造影测量的血管周围脂肪衰减指数(FAI)评估冠状动脉炎症。结果显示生物制剂组FAI显著下降,对照组无变化,提示生物制剂可能直接减轻冠状动脉炎症。

要点

  • 生物制剂治疗1年与银屑病患者血管周围FAI显著降低相关。
  • 未接受生物制剂者FAI无显著变化,支持抗炎治疗对冠状动脉的直接效应。
  • FAI变化独立于冠状动脉斑块存在,且在不同生物制剂间一致。

核心结论

  • 中重度银屑病患者接受生物制剂治疗1年与血管周围FAI所评估的冠状动脉炎症降低相关。
  • 该关联独立于基线冠状动脉斑块的存在,且在不同生物制剂间表现一致。

研究设计与样本

  • 前瞻性队列研究,2013年1月1日至2019年3月31日,纳入134例基线未接受生物制剂的中重度银屑病患者。
  • 所有患者基线和1年时接受冠状动脉CT血管造影(CCTA),由对患者信息不知情的读片者进行血管周围FAI标测。
  • 82例接受生物制剂治疗1年(抗TNF-α、抗IL-12/23或抗IL-17),52例未接受生物制剂(局部或光疗)作为对照组。

主要发现

  • 生物制剂组1年FAI较基线显著下降:中位FAI -71.22 HU(IQR -75.85至-68.11)降至-76.09 HU(IQR -80.08至-70.37),P < .001。
  • 对照组FAI无显著变化:中位FAI -71.98(IQR -77.36至-65.64)对-72.66(IQR -78.21至-67.44),P = .39。
  • 生物制剂组皮肤病变改善:中位PASI从7.7(IQR 3.2-12.5)降至3.2(IQR 1.8-5.7),P < .001。
  • 抗TNF-α亚组FAI显著下降:中位FAI -71.25(IQR -75.86至-66.89)降至-75.49(IQR -79.12至-68.58),P < .001。
  • 抗IL-12/23或抗IL-17亚组FAI显著下降:中位FAI -71.18(IQR -75.85至-68.80)降至-76.92(IQR -81.16至-71.67),P < .001。

临床怎么用

  • 对于中重度银屑病患者,生物制剂治疗可能通过直接抗炎作用降低冠状动脉炎症,FAI可作为监测治疗反应的影像学指标。
  • FAI由CCTA测量,可用于追踪冠状动脉疾病干预措施的效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Psoriasis is a chronic inflammatory skin disease associated with increased coronary plaque burden and cardiovascular events. Biologic therapy for psoriasis has been found to be favorably associated with luminal coronary plaque, but it is unclear whether these associations are attributable to direct anti-inflammatory effects on the coronary arteries. OBJECTIVE: To investigate the association of biologic therapy with coronary inflammation in patients with psoriasis using the perivascular fat attenuation index (FAI), a novel imaging biomarker that assesses coronary inflammation by mapping spatial changes of perivascular fat composition via coronary computed tomography angiography (CCTA). DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study performed from January 1, 2013, through March 31, 2019, analyzed changes in FAI in patients with moderate to severe psoriasis who underwent CCTA at baseline and at 1 year and were not receiving biologic psoriasis therapy at baseline. EXPOSURES: Biologic therapy for psoriasis. MAIN OUTCOMES AND MEASURES: Perivascular FAI mapping was performed based on an established method by a reader blinded to patient demographics, visit, and treatment status. RESULTS: Of the 134 patients (mean [SD] age, 51.1 [12.1] years; 84 [62.5%] male), most had low cardiovascular risk by traditional risk scores (median 10-year Framingham Risk Score, 3% [interquartile range, 1%-7%]) and moderate to severe skin disease. Of these patients, 82 received biologic psoriasis therapy (anti-tumor necrosis factor α, anti-interleukin [IL] 12/23, or anti-IL-17) for 1 year, and 52 did not receive any biologic therapy and were given topical or light therapy (control group). At baseline, 46 patients (27 in the treated group and 19 in the untreated group) had a focal coronary atherosclerotic plaque. Biologic therapy was associated with a significant decrease in FAI at 1 year (median FAI -71.22 HU [interquartile range (IQR), -75.85 to -68.11 HU] at baseline vs -76.09 HU [IQR, -80.08 to -70.37 HU] at 1 year; P < .001) concurrent with skin disease improvement (median PASI, 7.7 [IQR, 3.2-12.5] at baseline vs 3.2 [IQR, 1.8-5.7] at 1 year; P < .001), whereas no change in FAI was noted in those not receiving biologic therapy (median FAI, -71.98 [IQR, -77.36 to -65.64] at baseline vs -72.66 [IQR, -78.21 to -67.44] at 1 year; P = .39). The associations with FAI were independent of the presence of coronary plaque and were consistent among patients receiving different biologic agents, including anti-tumor necrosis factor α (median FAI, -71.25 [IQR, -75.86 to -66.89] at baseline vs -75.49 [IQR, -79.12 to -68.58] at 1 year; P < .001) and anti-IL-12/23 or anti-IL-17 therapy (median FAI, -71.18 [IQR, -75.85 to -68.80] at baseline vs -76.92 [IQR, -81.16 to -71.67] at 1 year; P < .001). CONCLUSIONS AND RELEVANCE: In this study, biologic therapy for moderate to severe psoriasis was associated with reduced coronary inflammation assessed by perivascular FAI. This finding suggests that perivascular FAI measured by CCTA may be used to track response to interventions for coronary artery disease.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Elnabawi YA, Oikonomou EK, Dey AK, et al. Association of Biologic Therapy With Coronary Inflammation in Patients With Psoriasis as Assessed by Perivascular Fat Attenuation Index. JAMA Cardiol. 2019. PMID: 31365032. doi:10.1001/jamacardio.2019.2589

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。